NYSE$IBIO
iBio Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
iBio's financial results for Q1 2022 were announced, along with a corporate update, which included adding a new anti-cancer target, initiating a research collaboration, and establishing a partnership for vaccine delivery.
iBio reported revenues of $211,000 for the first fiscal quarter ended September 30, 2021, a 49% decrease compared to the same period in 2020. The consolidated net loss for the quarter was $8.9 million, or $0.04 per share. The company had $82.3 million in cash and cash equivalents as of September 30, 2021.
- Added a new anti-cancer target for development in partnership with RubrYc Therapeutics.
- Initiated a research collaboration with UT Southwestern to study anti-fibrotics in oncology.
- Established a partnership for the development of painless intradermal vaccine delivery.
- Advanced novel COVID-19 vaccine candidate to pre-IND.
Headline financials
Revenue & EPS history
iBio · Revenue · Quarterly
$211K
Forward guidance
iBio is focused on delivering shareholder value across multiple fronts, including announcing new oncology targets and two possible IND filings. The company is excited about the partnership opportunities for its bioprocess business as industry awareness of the need to implement sustainable, ESG-based practices continues to grow.
Tailwinds
- Announcing new oncology targets
- Two possible IND filings
- Partnership opportunities for bioprocess business
- Industry awareness of sustainable practices
- Strategic and operational flexibility
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
-1.4%
Avg return
Earnings day
-2.9%
Avg return
5 days after
+14.3%
Avg return
30 days after
43%
17 / 40 earnings
Positive
+24.4%
Q3 2020
Best reaction
-34.4%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | +12.9% | +9.9% | +22.8% | |
| Q1 2026 | -8.0% | -3.2% | +55.2% | |
| Q4 2025 | +3.7% | +8.6% | +6.2% | |
| Q3 2025 | +1.3% | +1.3% | +30.4% | |
| Q2 2025 | -14.8% | -7.8% | +49.2% | |
| Q1 2025 | -9.4% | -10.9% | -2.0% | |
| Q4 2024 | -2.6% | -4.2% | +51.1% | |
| Q3 2026 | -3.7% | +23.9% | +36.2% | |
| Q3 2024 | +1.6% | +7.0% | +37.8% | |
| Q2 2024 | +5.2% | +5.2% | +2.6% | |
| Q1 2024 | -3.4% | -10.3% | -78.1% | |
| Q4 2023 | -3.3% | -9.1% | -6.1% | |
| Q3 2023 | -7.9% | -5.9% | -31.7% | |
| Q2 2023 | -10.5% | +55.8% | +113.7% | |
| Q1 2023 | +0.0% | -8.6% | -68.6% | |
| Q4 2022 | -34.4% | -46.9% | -74.6% | |
| Q3 2022 | +0.0% | +0.0% | +12.0% | |
| Q2 2022 | +2.7% | -8.1% | -5.4% | |
| Q1 2022 | -9.2% | -11.8% | -17.1% | |
| Q4 2021 | -4.3% | -11.1% | -35.0% | |
| Q3 2021 | -6.8% | -0.7% | +5.4% | |
| Q2 2021 | -15.3% | -17.8% | -29.8% | |
| Q1 2021 | +15.2% | -9.6% | -38.2% | |
| Q3 2020 | +24.4% | +16.0% | +31.9% | |
| Q2 2020 | -10.5% | -21.1% | +321.1% | |
| Q1 2020 | +13.3% | -26.7% | +46.7% | |
| Q3 2019 | +7.3% | -2.4% | -4.9% | |
| Q2 2019 | -2.2% | -4.4% | -6.7% | |
| Q1 2019 | +4.0% | +9.3% | -10.7% | |
| Q1 2015 | +3.4% | — | — | |
| Q1 2014 | +0.0% | — | — | |
| Q1 2013 | -1.9% | — | — | |
| Q3 2012 | -9.8% | — | — | |
| Q1 2010 | +1.8% | — | — | |
| Q1 2012 | +1.8% | — | — | |
| Q4 2011 | -3.0% | — | — | |
| Q3 2011 | +4.8% | — | — | |
| Q2 2010 | +3.4% | — | — | |
| Q4 2010 | +1.4% | — | — | |
| Q3 2010 | -1.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro